Premium
Failure of IMVP‐16 as second‐line treatment for relapsed or refractory high grade non‐hodgkin's lymphoma
Author(s) -
De Lord C.,
Newland A. C.,
Linch D. C.,
Hudson B. Vaughan,
Hudson G. Vaughan
Publication year - 1992
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2900100203
Subject(s) - medicine , ifosfamide , refractory (planetary science) , methotrexate , regimen , lymphoma , complete remission , salvage therapy , surgery , chemotherapy , gastroenterology , etoposide , physics , astrobiology
The British National Lymphoma Investigation (BNLI) has assessed the use of an IMVP‐16 regimen (ifosfamide, methotrexate, VP‐16) in 46 patients with high grade non‐Hodgkin's lymphoma (NHL) who on first‐line chemotherapy either failed to attain a complete remission or relapsed. Seventeen patients responded to IMVP‐16 but only five (11 per cent) went into a complete remission (CR), 12 (26 per cent) had a partial remission (PR) and 29 (63 per cent) showed no response (NR). CR after IMVP‐16 has been maintained in only one case (36 months). The results of this study imply that the use of this IMVP‐16 protocol as second‐line treatment for patients with recurrent high grade NHL is unsuccessful and alternative salvage regimens should be sought.